Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

High Levels of Low-Density Lipoproteins Correlate with Improved Survival in Patients with Squamous Cell Carcinoma of the Head and Neck

T. Wilms, L. Boldrup, X. Gu, PJ. Coates, N. Sgaramella, K. Nylander

. 2021 ; 9 (5) : . [pub] 20210504

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017827

Grantová podpora
NA Lion's Cancer Research Foundation, Umeå University
20 0754 PjF 01H The Swedish Cancer Society
NA Umeå University
NA Region Västerbotten
MMCI, 00209805 Ministry of Health Czech Republic, conceptual development of research organization

Circulating lipoproteins as risk factors or prognostic indicators for various cancers have been investigated previously; however, no clear consensus has been reached. In this study, we aimed at evaluating the impact of serum lipoproteins on the prognosis of patients with squamous cell carcinoma of the head and neck (SCCHN). Levels of total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides and lipoprotein(a) were measured in serum samples from 106 patients and 28 healthy controls. We found that HDL was the only lipoprotein exhibiting a significant difference in concentration between healthy controls and patients (p = 0.012). Kaplan-Meier survival curves indicated that patients with high levels of total cholesterol or LDL had better overall survival than patients with normal levels (p = 0.028 and p = 0.007, respectively). Looking at patients without lipid medication (n = 89) and adjusting for the effects of TNM stage and weight change, multivariate Cox regression models indicated that LDL was an independent prognostic factor for both overall (p = 0.005) and disease-free survival (p = 0.013). In summary, our study revealed that high LDL level is beneficial for survival outcome in patients with SCCHN. Use of cholesterol-lowering medicines for prevention or management of SCCHN needs to be evaluated carefully.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017827
003      
CZ-PrNML
005      
20210729104036.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines9050506 $2 doi
035    __
$a (PubMed)34064440
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Wilms, Torben $u Department of Medical Biosciences, Umea University, Umea, 901 87 Vasterbotten, Sweden $u Department of Clinical Sciences, Umea University, Umea, 901 87 Vasterbotten, Sweden
245    10
$a High Levels of Low-Density Lipoproteins Correlate with Improved Survival in Patients with Squamous Cell Carcinoma of the Head and Neck / $c T. Wilms, L. Boldrup, X. Gu, PJ. Coates, N. Sgaramella, K. Nylander
520    9_
$a Circulating lipoproteins as risk factors or prognostic indicators for various cancers have been investigated previously; however, no clear consensus has been reached. In this study, we aimed at evaluating the impact of serum lipoproteins on the prognosis of patients with squamous cell carcinoma of the head and neck (SCCHN). Levels of total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides and lipoprotein(a) were measured in serum samples from 106 patients and 28 healthy controls. We found that HDL was the only lipoprotein exhibiting a significant difference in concentration between healthy controls and patients (p = 0.012). Kaplan-Meier survival curves indicated that patients with high levels of total cholesterol or LDL had better overall survival than patients with normal levels (p = 0.028 and p = 0.007, respectively). Looking at patients without lipid medication (n = 89) and adjusting for the effects of TNM stage and weight change, multivariate Cox regression models indicated that LDL was an independent prognostic factor for both overall (p = 0.005) and disease-free survival (p = 0.013). In summary, our study revealed that high LDL level is beneficial for survival outcome in patients with SCCHN. Use of cholesterol-lowering medicines for prevention or management of SCCHN needs to be evaluated carefully.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Boldrup, Linda $u Department of Medical Biosciences, Umea University, Umea, 901 87 Vasterbotten, Sweden
700    1_
$a Gu, Xiaolian $u Department of Medical Biosciences, Umea University, Umea, 901 87 Vasterbotten, Sweden
700    1_
$a Coates, Philip J $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, 656 53 Southern Moravia, Czech Republic
700    1_
$a Sgaramella, Nicola $u Department of Medical Biosciences, Umea University, Umea, 901 87 Vasterbotten, Sweden
700    1_
$a Nylander, Karin $u Department of Medical Biosciences, Umea University, Umea, 901 87 Vasterbotten, Sweden
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 9, č. 5 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34064440 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104034 $b ABA008
999    __
$a ind $b bmc $g 1676434 $s 1138269
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c 5 $e 20210504 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
GRA    __
$a NA $p Lion's Cancer Research Foundation, Umeå University
GRA    __
$a 20 0754 PjF 01H $p The Swedish Cancer Society
GRA    __
$a NA $p Umeå University
GRA    __
$a NA $p Region Västerbotten
GRA    __
$a MMCI, 00209805 $p Ministry of Health Czech Republic, conceptual development of research organization
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...